HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

201.000

-3.200-1.57%

Volume:105.00K

Turnover:21.02M

Market Cap:15.82B

PE:67.55

High:204.200

Open:201.000

Low:196.600

Close:204.200

52wk High:302.400

52wk Low:97.500

Shares:78.71M

HK Float Shares:78.71M

Volume Ratio:0.37

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(LYR):2.976

ROE:16.58%

ROA:9.23%

PB:8.51

PE(LYR):67.55

PS:23.28

Loading ...

Overview Company News Filings

HAIXI PHARMA (02637) Announces New Board Appointments and Leadership Changes

Fujian Haixi Pharmaceuticals files directors list with Hong Kong Stock Exchange

Fujian Haixi Pharma amends articles, scraps board of supervisors in governance overhaul

Movement Alert｜Haixi New Drug Rises 5.37% in Regular Trading, Recovery Extends on Strong Annual Results and Broker Coverage

HAIXI PHARMA Registers Stable Share Base in April; Confirms Public Float Compliance

Bulletin Express

Stock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating

Stock Track | HAIXI PHARMA Plummets 8.35% Intraday on Lock-up Expiry Selling and Correction from Historical Highs

Haixi Pharma Sets 27 May 2026 AGM; Agenda Covers 19 Proposals Including Board Restructure, No 2025 Dividend and New Share Incentive Scheme

Bulletin Express

Haixi Pharma announces 27 May 2026 AGM; agenda covers capital increase, governance overhaul and new share mandates

Bulletin Express

Haixi Pharma Schedules 27 May 2026 AGM; Agenda Covers 2025 Results, Board Restructure and New Share Mandates

Bulletin Express

Fujian Haixi Pharmaceuticals announces annual general meeting

Stock Track | Haixi Pharma Soars 9.54% Intraday on Share Incentive Plan Announcement and Strong Fundamentals

HAIXI PHARMA Releases 2025 ESG Report, Sets 5% Carbon-Intensity Cut by 2030 and Highlights Zero Safety, Recall or Corruption Incidents

Bulletin Express

海西医药2025年业绩大增，营收同比增长24.8%至人民币5.82358亿元，持续加码双轨研发与全球化拓展

Bulletin Express

Fujian Haixi Pharmaceuticals publishes 2025 annual report

HAIXI PHARMA Proposes Adoption of H-Share Incentive Scheme

Fujian Haixi Pharma proposes H-share incentive scheme funded by existing shares

Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data

Haixi Pharma Adopts Full Electronic Dissemination of Corporate Communications

Bulletin Express

Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02637/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":201,"timestamp":1787299687040,"preClose":204.2,"halted":0,"volume":105000,"delay":0,"changeRate":-0.015670910871694362,"floatShares":78707270,"shares":78707270,"eps":2.975563205231751,"marketStatus":"Not Yet Opened","change":-3.2,"latestTime":"08-21 16:08:07","open":201,"high":204.2,"low":196.6,"amount":21020868,"amplitude":0.037218,"askPrice":206.8,"askSize":500,"bidPrice":201,"bidSize":550,"shortable":3,"etf":0,"ttmEps":2.9055499533439453,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":204.2,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.3655861566108926,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.975563,"volumeRatio":0.3655861566108926,"shares":78707270,"dividePrice":0,"high":204.2,"amplitude":0.037218,"preClose":204.2,"low":196.6,"week52Low":97.5,"pbRate":"8.51","psRate":"23.28","week52High":302.4,"institutionHeld":0,"latestPrice":201,"committee":0.047619,"eps":2.975563205231751,"divideRate":0,"volume":105000,"delay":0,"ttmEps":2.9055499533439453,"open":201,"prevYearClose":136,"prevWeekClose":204.8,"prevMonthClose":171,"prevQuarterClose":180,"fiveDayClose":204.8,"twentyDayClose":183.6,"sixtyDayClose":225.6,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-08-21","current":69.177954,"percent":0.731707,"low":41.43616,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"high":108.687128,"avg":73.776853,"sd":9.167145,"marketCap":15820161270},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270}],"updateTime":1787507364894},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1112742027","title":"HAIXI PHARMA (02637) Announces New Board Appointments and Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1112742027","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112742027?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:40","pubTimestamp":1779874834,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced that Dr. Chen Shuyi and Mr. Gong Weimin have retired as directors of the board following the conclusion of the annual general meeting. During the annual general...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638505283","title":"Fujian Haixi Pharmaceuticals files directors list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2638505283","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638505283?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:37","pubTimestamp":1779874674,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals filed an updated list of directors with the Hong Kong Stock Exchange on May 27, 2026.Board includes four executive directors, led by Chairman Dr. Kang Xinshan.Two non-executive directors serve alongside three independent non-executive directors.Committee chairs: Strategy—Dr. Kang Xinshan; Audit—Ms. Pu Meiting; Remuneration and Appraisal—Ms. Wang Shan Shan; Nomination—Ms. Wang Shan Shan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL7qy3jr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638460505","title":"Fujian Haixi Pharma amends articles, scraps board of supervisors in governance overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=2638460505","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638460505?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:36","pubTimestamp":1779874594,"startTime":"0","endTime":"0","summary":"Shareholders on May 27, 2026 passed amendments to the articles of association, with 99.9991% of votes cast in favor.Bylaw changes abolished the board of supervisors, effective immediately; oversight duties shift to the board’s audit committee.Related procedural rules were revised, including the rules for shareholder meetings and board meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL1N00gD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161926855","title":"Movement Alert｜Haixi New Drug Rises 5.37% in Regular Trading, Recovery Extends on Strong Annual Results and Broker Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1161926855","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161926855?lang=en_us&edition=fundamental","pubTime":"2026-05-20 14:43","pubTimestamp":1779259395,"startTime":"0","endTime":"0","summary":"On May 20, Haixi New Drug (02637.HK) rose 5.37% in regular trading, trading at 248.2 HKD/share, with trading volume of approximately 28.97 million HKD. The stock extended its rebound after fully...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112962796","title":"HAIXI PHARMA Registers Stable Share Base in April; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1112962796","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112962796?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:42","pubTimestamp":1778146968,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return with Hong Kong Exchanges and Clearing on 7 May 2026, covering movements up to 30 April 2026. The company reported no...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185030166","title":"Stock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1185030166","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185030166?lang=en_us&edition=fundamental","pubTime":"2026-05-05 09:42","pubTimestamp":1777945362,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 5.74% during intraday trading on Tuesday, marking a significant rebound.The sharp rise follows the company's release of its annual report, which showed revenue of RMB 582...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181538654","title":"Stock Track | HAIXI PHARMA Plummets 8.35% Intraday on Lock-up Expiry Selling and Correction from Historical Highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1181538654","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181538654?lang=en_us&edition=fundamental","pubTime":"2026-05-04 09:58","pubTimestamp":1777859931,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA's stock plummeted 8.35% during intraday trading on Monday, marking a significant decline for the pharmaceutical company.The sharp drop is primarily attributed to ongoing selling pressure...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166475230","title":"Haixi Pharma Sets 27 May 2026 AGM; Agenda Covers 19 Proposals Including Board Restructure, No 2025 Dividend and New Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1166475230","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166475230?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:43","pubTimestamp":1777556638,"startTime":"0","endTime":"0","summary":"Haixi Pharma will hold its annual general meeting on 27 May 2026 in Fuzhou, with shareholders asked to vote on 19 resolutions that together signal a comprehensive reshaping of the company’s...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186675778","title":"Haixi Pharma announces 27 May 2026 AGM; agenda covers capital increase, governance overhaul and new share mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1186675778","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186675778?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:43","pubTimestamp":1777556585,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (“Haixi Pharma”) has issued the proxy form and full agenda for its annual general meeting scheduled for 10:00 a.m. on 27 May 2026 at the company’s headquarters...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117452562","title":"Haixi Pharma Schedules 27 May 2026 AGM; Agenda Covers 2025 Results, Board Restructure and New Share Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1117452562","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117452562?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:42","pubTimestamp":1777556571,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) will convene its 2026 annual general meeting (AGM) on 27 May 2026 at 10:00 a.m. in Fuzhou, Fujian Province, the People’s Republic of China. Key...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631344653","title":"Fujian Haixi Pharmaceuticals announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631344653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631344653?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:39","pubTimestamp":1777556374,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals will hold annual general meeting in Fuzhou, Fujian Province on May 27, 2026.Shareholders will vote on 2025 results items, including audited financial statements, annual report, final accounts plan, profit distribution plan, auditor reappointment, directors’ 2026 remuneration, bank credit facilities up to RMB 1 billion, guarantees up to RMB 300 million.Governance proposals include abolishing board of supervisors, amendments to articles of association, amendments to board procedures, amendments to shareholders’ meeting procedures, election of second-session directors.Capital actions include raising authorized capital of Hong Kong subsidiary to HKD 300 million, adoption of 2026 share incentive implementation plan, 20% general mandate to issue shares, 10% general mandate to repurchase shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3c9JCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192464408","title":"Stock Track | Haixi Pharma Soars 9.54% Intraday on Share Incentive Plan Announcement and Strong Fundamentals","url":"https://stock-news.laohu8.com/highlight/detail?id=1192464408","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192464408?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:40","pubTimestamp":1777513208,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 9.54% during intraday trading, showing significant upward momentum in the market session.The company recently announced the adoption of an H-share incentive plan aimed at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189858473","title":"HAIXI PHARMA Releases 2025 ESG Report, Sets 5% Carbon-Intensity Cut by 2030 and Highlights Zero Safety, Recall or Corruption Incidents","url":"https://stock-news.laohu8.com/highlight/detail?id=1189858473","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189858473?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:24","pubTimestamp":1777469054,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) published its 2025 Environmental, Social and Governance Report covering operations from 1 January 2025 to 31 December 2025. The disclosure...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134020840","title":"海西医药2025年业绩大增，营收同比增长24.8%至人民币5.82358亿元，持续加码双轨研发与全球化拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=1134020840","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134020840?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:08","pubTimestamp":1777468116,"startTime":"0","endTime":"0","summary":"海西医药在截至2025年12月31日的财务数据显示，公司实现总收入人民币5.82358亿元（下同，以下金额如无特别说明均为已转换的“亿元”单位，即原公告“百万”单位数额÷100），较去年同期的4.66683亿元同比增长24.8%。其中，核心产品表现突出，带动整体业务规模稳步扩张。公司全年毛利为4.85557亿元，同比增长25.4%，毛利率由83.0%上升至83.4%。年内净利润达1.77029亿元...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西医药2025年业绩大增，营收同比增长24.8%至人民币5.82358亿元，持续加码双轨研发与全球化拓展","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631514990","title":"Fujian Haixi Pharmaceuticals publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631514990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631514990?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:55","pubTimestamp":1777467349,"startTime":"0","endTime":"0","summary":"HXPharma published its 2025 annual report, highlighting continued expansion of commercial footprint in China alongside a dual-track strategy combining generics with in-house innovative R&D.Portfolio reached 15 NMPA-cleared generic drugs, supported by distribution coverage of over 18,000 hospitals and medical institutions.National volume-based procurement products remained main growth drivers, led by Haihuitong and Anbili.Lead oncology candidate C019199 is slated to start Phase III osteosarcoma trials in 1H 2026, positioning it as potential first-in-class therapy.Oral retinal disease candidate HXP056 moved into Phase II in 4Q 2025, with US and China studies planned in 2026 for nAMD and DME.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5CrSfQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143765846","title":"HAIXI PHARMA Proposes Adoption of H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1143765846","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143765846?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:52","pubTimestamp":1777467143,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced that on April 29, 2026, the board of directors passed a resolution proposing the adoption of a share incentive plan applicable to the company's H-shares. The share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631514316","title":"Fujian Haixi Pharma proposes H-share incentive scheme funded by existing shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2631514316","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631514316?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:49","pubTimestamp":1777466955,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals board moved to adopt a share incentive scheme for H shares on April 29, 2026.Plan will be funded by existing shares, not new share issuance.Implementation requires shareholder approval via special resolution at upcoming annual general meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLRBdwQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119193958","title":"Stock Track | Haixi Pharma Soars 7.66% Intraday on Broker Initiation, Strong Financials and Positive Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1119193958","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119193958?lang=en_us&edition=fundamental","pubTime":"2026-04-29 10:00","pubTimestamp":1777428000,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 7.66% during intraday trading on Wednesday, staging a significant rebound.The movement follows the initiation of coverage by Shenwan Hongyuan with a Buy rating and a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137771673","title":"Haixi Pharma Adopts Full Electronic Dissemination of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1137771673","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137771673?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:24","pubTimestamp":1777382666,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) confirmed a transition to electronic delivery for all future corporate communications in line with Rule 2.07A of the Hong Kong Stock Exchange...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165703728","title":"Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1165703728","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165703728?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:23","pubTimestamp":1777382623,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":79,"code":"91000000","status":"200"}]}}